New Medication Release: Nucynta (Tapentadol)

The Food and Drug Administration (FDA) has approved Nucynta (tapentadol) tablets and Nucynta ER (tapentadol extended release) tablets for managing pain in adults.

Tapentadol immediate-release tablets are indicated to treat acute pain severe enough to require an opioid analgesic. These tablets are available in 50 mg, 75 mg, and 100 mg strengths.

Tapentadol extended-release tablets are indicated to treat severe, chronic pain, including nerve pain related to diabetic peripheral neuropathy. These tablets are available in 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg strengths.

Due to the serious risks associated with opioid medications—including addiction, misuse, overdose, and even death—these treatments are typically used only when other pain relief options are not effective.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at www.carlislemedical.com/services/retail-pharmacy-network/